|Day Low/High||0.32 / 0.33|
|52 Wk Low/High||0.27 / 3.94|
- Top-line data from PATENCY-2 expected in March of 2019 -
In recent trading, shares of Proteon Therapeutics Inc have crossed above the average analyst 12-month target price of $2.43, changing hands for $2.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Provides Sufficient Cash into Q4 2019
Depomed unveiled steps the company is taking to shore itself up.
Levi & Korsinsky announces it has commenced an investigation of Proteon Therapeutics, Inc.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.